-
1
-
-
0042626108
-
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease
-
Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
-
(2003)
Neurology
, vol.61
, pp. 293-296
-
-
Bara-Jimenez, W.1
Sherzai, A.2
Dimitrova, T.3
Favit, A.4
Bibbiani, F.5
Gillespie, M.6
Morris, M.J.7
Mouradian, M.M.8
Chase, T.N.9
-
2
-
-
0344630332
-
Translating A2A antagonist KW6002 from animal models to parkinsonian patients
-
Chase T.N., Bibbiani F., Bara-Jimenez W., Dimitrova T., and Oh-Lee J.D. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 61 (2003) S107-S111
-
(2003)
Neurology
, vol.61
-
-
Chase, T.N.1
Bibbiani, F.2
Bara-Jimenez, W.3
Dimitrova, T.4
Oh-Lee, J.D.5
-
3
-
-
3242765264
-
Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats
-
Coccurello R., Breysse N., and Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29 (2004) 1451-1461
-
(2004)
Neuropsychopharmacology
, vol.29
, pp. 1451-1461
-
-
Coccurello, R.1
Breysse, N.2
Amalric, M.3
-
4
-
-
0030615062
-
Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats
-
Fenu S., Pinna A., Ongini E., and Morelli M. Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321 (1997) 143-147
-
(1997)
Eur. J. Pharmacol.
, vol.321
, pp. 143-147
-
-
Fenu, S.1
Pinna, A.2
Ongini, E.3
Morelli, M.4
-
5
-
-
25444444802
-
Interactions between adenosine A(2a) and dopamine D2 receptors in the control of [(3)H]GABA release in the globus pallidus of the rat
-
Floran B., Gonzalez B., Floran L., Erlij D., and Aceves J. Interactions between adenosine A(2a) and dopamine D2 receptors in the control of [(3)H]GABA release in the globus pallidus of the rat. Eur. J. Pharmacol. 520 (2005) 43-50
-
(2005)
Eur. J. Pharmacol.
, vol.520
, pp. 43-50
-
-
Floran, B.1
Gonzalez, B.2
Floran, L.3
Erlij, D.4
Aceves, J.5
-
6
-
-
25844477182
-
Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function
-
Fuxe K., Ferre S., Canals M., Torvinen M., Terasmaa A., Marcellino D., Goldberg S.R., Staines W., Jacobsen K.X., Lluis C., Woods A.S., Agnati L.F., and Franco R. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci. 26 (2005) 209-220
-
(2005)
J. Mol. Neurosci.
, vol.26
, pp. 209-220
-
-
Fuxe, K.1
Ferre, S.2
Canals, M.3
Torvinen, M.4
Terasmaa, A.5
Marcellino, D.6
Goldberg, S.R.7
Staines, W.8
Jacobsen, K.X.9
Lluis, C.10
Woods, A.S.11
Agnati, L.F.12
Franco, R.13
-
7
-
-
0344052684
-
Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys
-
Grondin R., Bedard P.J., Hadj T.A., Gregoire L., Mori A., and Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
-
(1999)
Neurology
, vol.52
, pp. 1673-1677
-
-
Grondin, R.1
Bedard, P.J.2
Hadj, T.A.3
Gregoire, L.4
Mori, A.5
Kase, H.6
-
8
-
-
0035783949
-
Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats
-
Hauber W., Neuscheler P., Nagel J., and Muller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur. J. Neurosci. 14 (2001) 1287-1293
-
(2001)
Eur. J. Neurosci.
, vol.14
, pp. 1287-1293
-
-
Hauber, W.1
Neuscheler, P.2
Nagel, J.3
Muller, C.E.4
-
9
-
-
22344455811
-
Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience
-
Hauser R.A., and Schwarzschild M.A. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 22 (2005) 471-482
-
(2005)
Drugs Aging
, vol.22
, pp. 471-482
-
-
Hauser, R.A.1
Schwarzschild, M.A.2
-
10
-
-
0043126954
-
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD
-
Hauser R.A., Hubble J.P., and Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
-
(2003)
Neurology
, vol.61
, pp. 297-303
-
-
Hauser, R.A.1
Hubble, J.P.2
Truong, D.D.3
-
11
-
-
0035087868
-
Parkinson's disease therapy: treatment of early and late disease
-
Jankovic J. Parkinson's disease therapy: treatment of early and late disease. Chin. Med. J. (Engl.) 114 (2001) 227-234
-
(2001)
Chin. Med. J. (Engl.)
, vol.114
, pp. 227-234
-
-
Jankovic, J.1
-
12
-
-
21244440664
-
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease
-
Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs 14 (2005) 729-738
-
(2005)
Expert Opin. Investig. Drugs
, vol.14
, pp. 729-738
-
-
Jenner, P.1
-
13
-
-
0021273328
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset
-
Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., and Marsden C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50 (1984) 85-90
-
(1984)
Neurosci. Lett.
, vol.50
, pp. 85-90
-
-
Jenner, P.1
Rupniak, N.M.2
Rose, S.3
Kelly, E.4
Kilpatrick, G.5
Lees, A.6
Marsden, C.D.7
-
14
-
-
0344230823
-
Actions of adenosine antagonists in primate model of Parkinson's disease
-
Kase H., Richardson P.J., and Jenner P. (Eds), Academic Press, San Diego
-
Kanda T., and Jenner P. Actions of adenosine antagonists in primate model of Parkinson's disease. In: Kase H., Richardson P.J., and Jenner P. (Eds). Adenosine Receptors and Parkinson's Disease (2000), Academic Press, San Diego 211-227
-
(2000)
Adenosine Receptors and Parkinson's Disease
, pp. 211-227
-
-
Kanda, T.1
Jenner, P.2
-
15
-
-
0031594271
-
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
-
Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., and Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43 (1998) 507-513
-
(1998)
Ann. Neurol.
, vol.43
, pp. 507-513
-
-
Kanda, T.1
Jackson, M.J.2
Smith, L.A.3
Pearce, R.K.4
Nakamura, J.5
Kase, H.6
Kuwana, Y.7
Jenner, P.8
-
16
-
-
0032563388
-
Adenosine A2A receptors modify motor function in MPTP-treated common marmosets
-
Kanda T., Tashiro T., Kuwana Y., and Jenner P. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. NeuroReport 9 (1998) 2857-2860
-
(1998)
NeuroReport
, vol.9
, pp. 2857-2860
-
-
Kanda, T.1
Tashiro, T.2
Kuwana, Y.3
Jenner, P.4
-
17
-
-
0034049544
-
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
-
Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., and Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162 (2000) 321-327
-
(2000)
Exp. Neurol.
, vol.162
, pp. 321-327
-
-
Kanda, T.1
Jackson, M.J.2
Smith, L.A.3
Pearce, R.K.4
Nakamura, J.5
Kase, H.6
Kuwana, Y.7
Jenner, P.8
-
18
-
-
0035404473
-
New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia
-
Kase H. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci. Biotechnol. Biochem. 65 (2001) 1447-1457
-
(2001)
Biosci. Biotechnol. Biochem.
, vol.65
, pp. 1447-1457
-
-
Kase, H.1
-
19
-
-
0034711582
-
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats
-
Koga K., Kurokawa M., Ochi M., Nakamura J., and Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur. J. Pharmacol. 408 (2000) 249-255
-
(2000)
Eur. J. Pharmacol.
, vol.408
, pp. 249-255
-
-
Koga, K.1
Kurokawa, M.2
Ochi, M.3
Nakamura, J.4
Kuwana, Y.5
-
20
-
-
0027991686
-
Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release
-
Kurokawa M., Kirk I.P., Kirkpatrick K.A., Kase H., and Richardson P.J. Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release. Br. J. Pharmacol. 113 (1994) 43-48
-
(1994)
Br. J. Pharmacol.
, vol.113
, pp. 43-48
-
-
Kurokawa, M.1
Kirk, I.P.2
Kirkpatrick, K.A.3
Kase, H.4
Richardson, P.J.5
-
21
-
-
27444442267
-
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization
-
Minetti P., Tinti M.O., Carminati P., Castorina M., Di Cesare M.A., Di S.S., Gallo G., Ghirardi O., Giorgi F., Giorgi L., Piersanti G., Bartoccini F., and Tarzia G. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J. Med. Chem. 48 (2005) 6887-6896
-
(2005)
J. Med. Chem.
, vol.48
, pp. 6887-6896
-
-
Minetti, P.1
Tinti, M.O.2
Carminati, P.3
Castorina, M.4
Di Cesare, M.A.5
Di, S.S.6
Gallo, G.7
Ghirardi, O.8
Giorgi, F.9
Giorgi, L.10
Piersanti, G.11
Bartoccini, F.12
Tarzia, G.13
-
22
-
-
0034667715
-
A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease
-
Nash J.E., and Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 20 (2000) 7782-7789
-
(2000)
J. Neurosci.
, vol.20
, pp. 7782-7789
-
-
Nash, J.E.1
Brotchie, J.M.2
-
23
-
-
0141744657
-
Present and future directions in the management of motor complications in patients with advanced PD
-
Olanow C.W. Present and future directions in the management of motor complications in patients with advanced PD. Neurology 61 (2003) S24-S33
-
(2003)
Neurology
, vol.61
-
-
Olanow, C.W.1
-
24
-
-
0029417121
-
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)
-
Pearce R.K., Jackson M., Smith L., Jenner P., and Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. 10 (1995) 731-740
-
(1995)
Mov. Disord.
, vol.10
, pp. 731-740
-
-
Pearce, R.K.1
Jackson, M.2
Smith, L.3
Jenner, P.4
Marsden, C.D.5
-
25
-
-
0029666492
-
Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats
-
Pinna A., di Chiara C.G., Wardas J., and Morelli M. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur. J. Neurosci. 8 (1996) 1176-1181
-
(1996)
Eur. J. Neurosci.
, vol.8
, pp. 1176-1181
-
-
Pinna, A.1
di Chiara, C.G.2
Wardas, J.3
Morelli, M.4
-
26
-
-
17444413762
-
New adenosine A2A receptor antagonists: actions on Parkinson's disease models
-
Pinna A., Volpini R., Cristalli G., and Morelli M. New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur. J. Pharmacol. 512 (2005) 157-164
-
(2005)
Eur. J. Pharmacol.
, vol.512
, pp. 157-164
-
-
Pinna, A.1
Volpini, R.2
Cristalli, G.3
Morelli, M.4
-
27
-
-
0034856088
-
The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors
-
Popoli P., Pezzola A., Torvinen M., Reggio R., Pintor A., Scarchilli L., Fuxe K., and Ferre S. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25 (2001) 505-513
-
(2001)
Neuropsychopharmacology
, vol.25
, pp. 505-513
-
-
Popoli, P.1
Pezzola, A.2
Torvinen, M.3
Reggio, R.4
Pintor, A.5
Scarchilli, L.6
Fuxe, K.7
Ferre, S.8
-
28
-
-
13244264871
-
Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum
-
Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92 (2005) 433-441
-
(2005)
J. Neurochem.
, vol.92
, pp. 433-441
-
-
Rodrigues, R.J.1
Alfaro, T.M.2
Rebola, N.3
Oliveira, C.R.4
Cunha, R.A.5
-
29
-
-
33748465835
-
-
Rose, S., Croft, N., Jenner, P., in press. The novel adenosine antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in unilaterally 6-OHDA lesioned rats. Brain Res.
-
-
-
-
30
-
-
0026326607
-
Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study
-
Schiffmann S.N., Jacobs O., and Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57 (1991) 1062-1067
-
(1991)
J. Neurochem.
, vol.57
, pp. 1062-1067
-
-
Schiffmann, S.N.1
Jacobs, O.2
Vanderhaeghen, J.J.3
-
32
-
-
0029989550
-
An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets
-
Smith L., De Salvia S.M., Jenner P., and Marsden C.D. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov. Disord. 11 (1996) 125-135
-
(1996)
Mov. Disord.
, vol.11
, pp. 125-135
-
-
Smith, L.1
De Salvia, S.M.2
Jenner, P.3
Marsden, C.D.4
-
33
-
-
33748446549
-
-
Stasi, M., Borsini, F., Varani, K., Vincenzi, F., Di Cesare, M., Minetti, P., Ghirardi, O., Carminati, P., in press. ST1535: A preferential A2a adenosine receptor antagonist. Int. J. Neuropsychopharm. [Epublication ahead of print].
-
-
-
-
34
-
-
0041659345
-
Prevention and treatment of motor fluctuations
-
Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat. Disord. 9 Suppl 2 (2003) S73-S81
-
(2003)
Parkinsonism Relat. Disord.
, vol.9
, Issue.SUPPL. 2
-
-
Stocchi, F.1
-
35
-
-
0005866578
-
Selective adenosine A2a receptor antagonism as an alternative therapy for Parkinson's disease: a study in non-human primates
-
Kase H., Richardson P.J., and Jenner P. (Eds), Academic Press, San Diego
-
Tadj Tahar A., Grondin R., Gregoire L., and Bedard P.J. Selective adenosine A2a receptor antagonism as an alternative therapy for Parkinson's disease: a study in non-human primates. In: Kase H., Richardson P.J., and Jenner P. (Eds). Adenosine Receptors and Parkinson's Disease (2000), Academic Press, San Diego 229-244
-
(2000)
Adenosine Receptors and Parkinson's Disease
, pp. 229-244
-
-
Tadj Tahar, A.1
Grondin, R.2
Gregoire, L.3
Bedard, P.J.4
|